Emphasizes the need to differentiate true resistant hypertension from pseudoresistance and to individualize treatment.
Answers are grounded in this paper and cite their sources.
Requires careful differentiation of pseudoresistance before escalation; leaves open optimal individualized strategies for prospective study.
True refractory hypertension is relatively rare, but the causes of pseudoresistance are many. Thus, all patients should be considered medically treatable until proved otherwise. Initial workup should seek to determine whether the patient, the physician, or the hypertension is resistant. And one must make sure that therapy is indeed tailored to the patient's individual pathophysiology.
No takes yet. Share an insight, caveat, or question.
Robert C. Tarazi (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: